TY - JOUR

T1 - Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis

AU - Makshakov, Gleb

AU - Magonov, Evgeniy

AU - Totolyan, Natalia

AU - Nazarov, Vladimir

AU - Lapin, Sergey

AU - Mazing, Alexandra

AU - Verbitskaya, Elena

AU - Trofimova, Tatiana

AU - Krasnov, Vladimir

AU - Shumilina, Maria

AU - Skoromets, Alexander

AU - Evdoshenko, Evgeniy

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-Attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.

AB - Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-Attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.

UR - http://www.scopus.com/inward/record.url?scp=85031911300&partnerID=8YFLogxK

U2 - 10.1155/2017/8652463

DO - 10.1155/2017/8652463

M3 - Article

AN - SCOPUS:85031911300

VL - 2017

JO - Neurology Research International

JF - Neurology Research International

SN - 2090-1852

M1 - 8652463

ER -